Kevin Hrusovosky’s career has been dedicated to transforming medicine from reactive “sick care” to preventative personalized care. A serial entrepreneur, he currently serves as the CEO of Quanterix, a company which has just nabbed $700 million and is raising the bar on proteomics testing.
“Genomics can tell you what your predisposition is,” he says in today’s interview, “proteomics can tell you the earliest moment you are in a disease cascade.”
Quanterix has, like many other companies in the past year, added COVID testing to their lineup. Where they have made their mark in the pandemic as well as in many other disease areas is with the high sensitivity of their testing. This new sensitivity will ultimately lead to high quality, at-home COVID testing and coupled with wearables, early preventative testing for other diseases, says Kevin.
Tests that are up to 1000 times more sensitive than older technologies are opening up opportunities in early detection of cancer, infectious disease, and heart disease. Kevin believes we will see a shift in the testing paradigm. Patients will be tested earlier: not just when they have symptoms, but when they are asymptomatic or pre-symptomatic. The company is also working with pharmaceutical companies to better stratify patients for Alzheimer’s trials.
How will patients know to be tested if they are pre-symptomatic? How does Kevin see the proteomics tools space compared to that of genomics?
Join us as we zoom out from the pandemic to look at the precision health movement as powered by proteomics.